CDK5: Insights into Its Roles in Diseases

Overview

Journal Mol Biol Rep

Date 2025 Jan 21

PMID 39836243

Authors

Jiahui Wang

Chong Zhang

Tingting Jiang

Yi He

Yongli Wu

Dongsheng Zhou

Jianguo Yan

Yali Zhou

Affiliations

Soon will be listed here.

Abstract

Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family, is a proline-directed serine/threonine protein kinase with critical roles in various physiological and pathological processes. Widely expressed in the central nervous system, CDK5 is strongly implicated in neurological diseases. Beyond its neurological roles, CDK5 is involved in metabolic disorders, psychiatric conditions, and tumor progression, contributing to processes such as proliferation, migration, immune evasion, genomic stability, and angiogenesis. This review explores the structure and biological functions of CDK5, highlighting its regulatory roles in disease development through the phosphorylation of diverse substrate proteins. Additionally, we examine the therapeutic potential of CDK5 inhibition, offering novel perspectives for disease diagnosis and treatment.

References

Shupp A, Casimiro M, Pestell R . Biological functions of CDK5 and potential CDK5 targeted clinical treatments. Oncotarget. 2017; 8(10):17373-17382. PMC: 5370047. DOI: 10.18632/oncotarget.14538. View

Zhang B, Tan V, Lim K, Tay T . The activation and inhibition of cyclin-dependent kinase-5 by phosphorylation. Biochemistry. 2007; 46(38):10841-51. DOI: 10.1021/bi700890t. View

Ohshima T, Ward J, Huh C, Longenecker G, Veeranna , Pant H . Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A. 1996; 93(20):11173-8. PMC: 38303. DOI: 10.1073/pnas.93.20.11173. View

Jahan I, Adachi R, Egawa R, Nomura H, Kuba H . CDK5/p35-Dependent Microtubule Reorganization Contributes to Homeostatic Shortening of the Axon Initial Segment. J Neurosci. 2023; 43(3):359-372. PMC: 9864565. DOI: 10.1523/JNEUROSCI.0917-22.2022. View

Huang H, Lin X, Liang Z, Zhao T, Du S, Loy M . Cdk5-dependent phosphorylation of liprinα1 mediates neuronal activity-dependent synapse development. Proc Natl Acad Sci U S A. 2017; 114(33):E6992-E7001. PMC: 5565463. DOI: 10.1073/pnas.1708240114. View

Montenegro-Venegas C, Guhathakurta D, Pina-Fernandez E, Andres-Alonso M, Plattner F, Gundelfinger E . Bassoon controls synaptic vesicle release via regulation of presynaptic phosphorylation and cAMP. EMBO Rep. 2022; 23(8):e53659. PMC: 9346490. DOI: 10.15252/embr.202153659. View

Garemilla S, Kumari R, Kumar R . CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review. Eur J Pharmacol. 2024; 978:176760. DOI: 10.1016/j.ejphar.2024.176760. View

Kimura T, Ishiguro K, Hisanaga S . Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci. 2014; 7:65. PMC: 4097945. DOI: 10.3389/fnmol.2014.00065. View

AvilesRosas V, RendonOchoa E, Hernandez-Flores T, Flores-Leon M, Arias C, Galarraga E . Role of M -receptor cholinergic signaling in direct pathway striatal projection neurons during dopamine depletion. Synapse. 2024; 78(2):e22287. DOI: 10.1002/syn.22287. View

10.

Avraham E, Rott R, Liani E, Szargel R, Engelender S . Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem. 2007; 282(17):12842-50. DOI: 10.1074/jbc.M608243200. View

11.

Xu X, Li M, Su Y, Wang Q, Qin P, Huang H . Cdk5 phosphorylation-dependent C9orf72 degradation promotes neuronal death in Parkinson's disease models. CNS Neurosci Ther. 2023; 29(12):3952-3966. PMC: 10651984. DOI: 10.1111/cns.14319. View

12.

Lopez-Grueso M, Padilla C, Barcena J, Requejo-Aguilar R . Deficiency of Parkinson's Related Protein DJ-1 Alters Cdk5 Signalling and Induces Neuronal Death by Aberrant Cell Cycle Re-entry. Cell Mol Neurobiol. 2022; 43(2):757-769. PMC: 9958167. DOI: 10.1007/s10571-022-01206-7. View

13.

Quan Q, Li X, Feng J, Hou J, Li M, Zhang B . Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease. Mol Med Rep. 2020; 22(4):3277-3288. PMC: 7453505. DOI: 10.3892/mmr.2020.11424. View

14.

Chen H, Deng C, Meng Z, Zhu M, Yang R, Yuan J . Combined Catalpol and Tetramethylpyrazine Promote Axonal Plasticity in Alzheimer's Disease by Inducing Astrocytes to Secrete Exosomes Carrying CDK5 mRNA and Regulating STAT3 Phosphorylation. Mol Neurobiol. 2024; 61(12):10770-10791. DOI: 10.1007/s12035-024-04251-z. View

15.

Nikhil K, Shah K . The Cdk5-Mcl-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer's disease. J Cell Sci. 2017; 130(18):3023-3039. PMC: 5612176. DOI: 10.1242/jcs.205666. View

16.

Cole A, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D . Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem. 2007; 103(3):1132-44. DOI: 10.1111/j.1471-4159.2007.04829.x. View

17.

Saito T, Oba T, Shimizu S, Asada A, Iijima K, Ando K . Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262. Hum Mol Genet. 2019; 28(18):3062-3071. DOI: 10.1093/hmg/ddz120. View

18.

Park J, Seo J, Won J, Yeo H, Ahn Y, Kim K . Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling. Exp Neurobiol. 2019; 28(3):414-424. PMC: 6614070. DOI: 10.5607/en.2019.28.3.414. View

19.

Gomez K, Vallecillo T, Moutal A, Perez-Miller S, Delgado-Lezama R, Felix R . The role of cyclin-dependent kinase 5 in neuropathic pain. Pain. 2020; 161(12):2674-2689. PMC: 7669638. DOI: 10.1097/j.pain.0000000000002027. View

20.

Pareek T, Kulkarni A . Cdk5: a new player in pain signaling. Cell Cycle. 2006; 5(6):585-8. DOI: 10.4161/cc.5.6.2578. View